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San Francisco, CA 94143, USA; 3Drug Metabolism and Pharmacokinetics – Bioanalytics, Bayer Schering Pharma AG, Mu¨llerstr, Berlin, Germany
BACKGROUND: Sagopilone is a novel fully synthetic epothilone with promising preclinical activity and a favourable toxicity profile in
phase I testing.
METHODS: A phase II pharmacokinetic and efficacy trial was conducted in patients with metastatic melanoma. Patients had measurable
disease, Eastern Cooperative Oncology Group performance status 0–2, adequate haematological, and organ function, with up to
2 previous chemotherapy and any previous immunotherapy regimens. Sagopilone, 16mgm2, was administered intravenously over
3 h every 21 days until progression or unacceptable toxicity.
RESULTS: Thirty-five patients were treated. Sagopilone showed multi-exponential kinetics with a mean terminal half-life of 64 h and a
volume of distribution of 4361 lm2 indicating extensive tissue/tubulin binding. Only grade 2 or lower toxicity was observed: these
included sensory neuropathy (66%), leukopenia (46%), fatigue (34%), and neutropenia (31%). The objective response rate was 11.4%
(one confirmed complete response, two confirmed partial responses, and one unconfirmed partial response). Stable disease for at
least 12 weeks was seen in an additional eight patients (clinical benefit rate 36.4%).
CONCLUSION: Sagopilone was well tolerated with mild haematological toxicity and sensory neuropathy. Unlike other epothilones,
it shows activity against melanoma even in pretreated patients. Further clinical testing is warranted.
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Melanoma is the most aggressive type of skin cancer; it is rapidly
increasing in incidence worldwide. It is estimated that over 60 000
new cases and over 8000 deaths (Jemal et al, 2008) resulted from
this disease in the United States in 2008. The overall prognosis of
metastatic melanoma remains very poor (Barth et al, 1995) owing
to the lack of effective, tolerable, non-cross-resistant therapeutic
options. Current therapeutic options are poor and are not
associated with a survival benefit (Atkins et al, 1999, 2000).
Taxane-based combinations are emerging as a treatment option
in melanoma, despite significant limitations. Although phase II
trials of paclitaxel have reported varying degrees of efficacy, a
recent, large phase III trial of single-agent paclitaxel in front-line
metastatic melanoma patients showed very low objective response
rates (4.4%) and limited median overall survival (Einzig et al, 1991;
Aamdal et al, 1994; Bedikian et al, 1995; Hauschild et al, 2009a, b).
However, in combination with carboplatin, responses have been
seen in 11–36% (Hauschild et al, 2009a) of pretreated patients.
Paclitaxel has several other drawbacks; owing to its insolubility,
it is solubilised with Cremophor EL, a castor oil derivative that
can induce potentially life-threatening hypersensitivity reactions
(ten Tije et al, 2003). In addition, taxanes have poor penetration
into the central nervous system (Glantz et al, 1995), limiting their
utility in melanoma where CNS involvement is common, and they
are susceptible to chemotherapy resistance mechanisms such as
overexpression of the multidrug resistance-1 (MDR-1) transporter
(Fojo and Menefee, 2007).
Epothilones are a newer class of microtubule-stabilising agents
designed to overcome some of the limitations of taxanes. Although
some epothilones, notably ixabepilone, have proven their efficacy
in both taxane-sensitive and taxane-refractory solid tumours (Low
et al, 2005; Perez et al, 2007; Rosenberg et al, 2007; Vansteenkiste
et al, 2007; Burtness et al, 2008; Thomas, 2008), in melanoma,
epothilones have so far failed to show significant activity. For
example, patupilone showed no activity in one study (Daud, 2009),
and ixabepilone, a second-generation epothilone showed no
objective tumour responses, and significant treatment-related
toxicities (Pavlick et al, 2004).
Preclinical data suggest that sagopilone (also called ZK-EPO), a
fully-synthetic, third-generation epothilone may be more effective
than other tubulin-active drugs in patients with advanced
melanoma. Sagopilone evades the MDR-1 efflux pump, and, unlike
the earlier generation epothilones, it is rapidly and efficiently taken
up into tumour cells (Klar et al, 2006; Hoffmann et al, 2008). In a
phase I clinical trial in patients with advanced solid tumours,
antitumour activity was observed in 15 of 44 patients, including
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at least one patient with ocular melanoma (Schmid et al, 2010).
Phase II trials have shown that sagopilone is active in ovarian
cancer (Rustin et al, 2007; McMeekin et al, 2008), small-cell lung
cancer (Gatzemeier et al, 2007; Fischer et al, 2008), and androgen-
independent prostate cancer (Beer et al, 2008; Graff et al, 2008).
Unlike taxanes and some epothilones, sagopilone crosses the
blood–brain barrier, and antitumour efficacy has been shown in a
xenograft model of melanoma brain metastases (Hoffmann et al,
2009) and in brain metastases from small-cell lung cancer
(Christoph et al, 2009).
Sagopilone also has a more favourable toxicity profile than
other tubulin-active drugs. Sagopilone is more water soluble
than earlier epothilones, and formulation with Cremophor EL
is not required (Klar et al, 2006; Hoffmann et al, 2008). The
most common toxicities associated with sagopilone at the
recommended phase II dose of 16mgm2 every 21 days have
included grade 1–2 peripheral sensory neuropathy, fatigue,
nausea, and, less commonly, mild haematological toxicity (Rustin
et al, 2007).
We conducted a phase II trial of sagopilone in patients with
metastatic melanoma to determine whether it has the potential to
expand the therapeutic arsenal of non-cross-resistant chemother-
apeutics in metastatic melanoma.
METHODS
Study design
This was a prospective, single arm, phase II trial designed to
determine the magnitude of benefit and safety profile of sagopilone
in melanoma. In addition, the first 10 patients underwent
pharmacokinetic testing and evaluation. The trial was approved
by the Scientific Review Committee and the Institutional Review
Board at the Moffitt Cancer Center. Accrual began in May 2007 and
was completed in October 2008.
Patients
Eligible patients had to have unresectable stage III or stage IV
melanoma with measurable disease by the Response Evaluation
Criteria in Solid Tumours (RECIST) (Therasse et al, 2000).
Treatment with up to two previous chemotherapy regimens was
allowed as long as there had been no previous treatment with
tubulin-active drugs that are similar in mechanism of action to
sagopilone, such as other epothilones, taxanes, or vinca alkaloids.
Patients had to be X18 years of age with an Eastern Cooperative
Oncology Group performance status of 0–2, adequate bone
marrow function (white blood cell count 43.0 109 l1, haemo-
globin 410 g dl1, platelets 4109 l1), adequate hepatic function
(total bilirubino1.5 times the upper limit of normal, and AST and
ALT o5 times the upper limit of normal), and adequate renal
function (creatinine less than 2mgdl1). Patients were excluded
if they had New York Heart Association class III or IV congestive
heart failure, unstable angina pectoris, or cardiac arrhythmias
requiring continuous treatment. Patients with grade 2 or higher
sensory neuropathy of any aetiology were also excluded due
concern that sagopilone could exacerbate their symptoms. Patients
with CNS involvement were eligible if they were asymptomatic,
and if the lesions were radiographically stable over a period of
at least 8 weeks.
Study treatment
Patients were treated with 16mgm2 of sagopilone administered
as a single 3-h intravenous infusion every 21 days. Before each
treatment, patients were premedicated with either granisetron or
ondansetron and additional antiemetics if needed. Chemotherapy
was continued until disease progression, withdrawal of consent,
or for unacceptable treatment-associated toxicity. Treatment was
discontinued if a patient incurred grade 4 neurotoxicity or grade
2 or higher neurotoxicity lasting longer than 5 weeks with or
without treatment delays. Any other grade 3 or 4 toxicity that
persisted despite maximal supportive care led to dose reduction,
treatment interruption, or discontinuation of sagopilone therapy at
the discretion of the investigators.
Bioanalysis
Plasma levels of sagopilone were determined by liquid chromato-
graphy/mass spectrometry (LC/MS/MS) (US Food and Drug
Administration, 2001) in the first 10 patients on the study.
Samples were obtained at the following time points: before the
initiation of sagopilone; at 30, 175, 190, and 210min; at 5, 8, and
27 h; and at 1 week after the initiation of the infusion. In all cases,
1ml blood samples were collected in lithium heparin tubes,
stabilised by Pefabloc, and centrifuged at 4000 r.p.m. for 10min
within 30min after collection. From the supernatant, two aliquots
of 250 ml were transferred into test tubes and stored at 801C until
analysis. The quantitative analysis of sagopilone plasma
levels was performed at the Function Bioanalytics Laboratory,
Bayer Schering Pharma AG Berlin, Germany. In a first step,
sagopilone was isolated from the plasma by liquid–liquid
extraction, followed by the LC/MS/MS analysis. The lower limit
of quantification (LLOQ) for the determination of sagopilone
concentrations in human Li-heparin plasma containing Pefabloc
was established to be 100 pgml1 during method validation. In this
study, accuracy and precision was ensured by means of quality
control samples. Over the calibrated range (0.100–100 ngml1),
the mean accuracy varied from 98.0 to 111% and the precision
from 4.4 to 8.7%.
Pharmacokinetics
Pharmacokinetic parameters were calculated using the standard
software (EPSKinetica, version 2.6.1, Thermo Fisher Scientific,
Waltham, MA, USA) without recourse to model assumptions.
The pharmacokinetic evaluation was based on individual plasma
concentration–time values of sagopilone using actual blood sampling
times. Cmax and Tmax were directly read off the concentration–time
profiles. The area under the curve (AUCð0  tlastÞ and AUC) was
calculated according to the mixed log–linear trapezoidal rule.
All plasma concentration values below the LLOQ were set to
zero. The terminal disposition rate constant (lz) was calculated
by means of regression analysis of the perceivable linear part of
the curve in a semilogarithmic plot (lz: slope of the regression
line). The corresponding terminal half-life (t1/2) was calculated by:
t1/2¼ ln2/lz. Individual values were not accepted if the time
range covered by the perceivable linear part of the curve was
less than two half-lives. In all cases, at least three data points were
used for the half-life calculation of each disposition phase. The
AUC was calculated according to the following equation:
AUC¼AUCtlast þ (computed Clast/lz), with computed Clast being
the concentration calculated for the time point (tlast) with the last
quantifiable concentration, and lz being the terminal disposition
rate constant.
Response assessment
The primary end point in this study was assessment of objective
tumour response by the RECIST criteria. Secondary end points
included time to progression, overall survival, and tolerability.
Tumour assessments using the modified RECIST criteria were
made at baseline and at the end of every second cycle (i.e. every
6 weeks). Partial and complete responses were defined by the
best treatment response achieved. Stable disease was defined as
maintenance between a 30% reduction and a 20% increase of
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tumour size over 12 weeks or longer. Stable disease was measured
from the start of the treatment until the criteria for disease
progression were met, and formal radiographic confirmation was
not required in accordance with the RECIST criteria. Patients were
assessed for adverse events based on clinical and laboratory data
on treatment days 1, 8, and 15 of the first 21-day cycle, and then
every 3 weeks on day 1 of each subsequent cycle.
Statistics
A Gehan–Simon optimal two-stage trial design was used to limit
patient accrual in case the trial drug proved ineffective. Accrual
of 33 evaluable patients was planned; if at least 1 of the first
15 patients had an objective response as defined by the RECIST
criteria, accrual would continue. The ‘null’ hypothesis assumed a
response probability of 1% (spontaneous remission), whereas the
target response rate was 15%. The alpha level of the design was
0.03 and the power was 90%. Descriptive Kaplan–Meier survival
analysis was performed and subgroup survival comparisons
using log-rank were performed using SPSS version 17 (Chicago,
IL, USA). Adverse events were graded using the Common
Terminology Criteria for Adverse Events version 3.0.
RESULTS
Patients
Thirty-nine patients were consented and screened for this trial.
Four were ineligible based on the screening criteria and were
not treated with sagopilone. Thirty-five patients, all with stage
IV melanoma, were treated with at least one dose of sagopilone
and included in response and toxicity assessments. Patient
demographics, staging information, and previous treatment
histories are summarised in Table 1. The majority of patients
had stage IVC disease (74.3%) and lactate dehydrogenase
(LDH) elevations were seen in nearly half of patients (45.7%).
Most patients (65.7%) had been treated previously with cyto-
toxic chemotherapy (including two treated regionally with isolated
limb perfusion) and a substantial proportion had received
immunotherapy (28.6%). Twenty-one patients (60%) received
dacarbazine or temozolomide. Two patients were previously
exposed to cisplatin. The average number of chemotherapy cycles
received was three or fewer for each regimen, except for the
combination of karenitecin with valproic acid. Two patients
were treated with this combination received an average of
10 cycles. The median age of the patients treated in this study
was 68.7 (±1.7 years).
Pharmacokinetics
Nine of the subjects were evaluable since one patient was excluded
from the PK analysis owing to three missing PK samples necessary
to define the Cmax and AUC. Maximum average sagopilone
concentrations of 33.3 ngml1 were reached 2.92 h after the start
of the infusion (Figure 1). Plasma concentrations dropped about
10-fold within 30min after the end of infusion. Thereafter, the
concentration–time profile turned into a slow terminal disposition
phase. Drug disposition appeared to be multi-exponential, with
sagopilone plasma concentrations decreasing to about 10% of peak
concentration by 0.5 h after the end of the 3-h intravenous
infusion. After the rapid distribution phase, a long terminal
disposition phase followed (mean terminal half-life 64.1 h). The
large apparent volume of distribution indicates extensive tissue/
tubulin binding. Therefore, the long terminal half-life was thought
to reflect the release of sagopilone from deep tissue compartments
rather than the actual rate of its metabolism or excretion. The
rate of total body clearance was 120 l h1 (2000mlmin1) and
the apparent volume of distribution during the terminal
phase was 4361 lm2. The net average area under the plasma
concentration–time curve was 252 ng.hml1. The kinetic para-
meter estimates observed in this study were similar to those
Table 1 Patient demographics, stage, and previous treatment
Factor Category N %
Gender Male 24 68.6
Female 11 31.4
Stage IV – M1a 1 2.9
IV – M1b 8 22.9
IV – M1c 26 74.3
Previous
treatments
Surgery 29 82.9
Radiation 7 20.0
Chemotherapy Actinomycin D 1 2.9
Carmustine 1 2.9
Cisplatin 2 5.7
DTIC/temozolomide 21 60.0
Karenitecin 2 5.7
Melphalan ILP 2 5.7
Immunotherapy Interferon 9 25.7
IL-2 2 5.7
Ipilimumab 1 2.9
Intralesional GM-CSF 1 2.9
IL-12 electroporation 1 2.9
Kinase inhibitors Sunitinib 1 2.9
Dasatinib 1 2.9
ATN 224-007 1 2.9
HDAC inhibitor Valproic acid 2 5.7
Patients treated previously Adjuvant/regional 14 40.0
For systemic disease 21 60.0
Baseline LDH Normal 19 54.3
Elevated 16 45.7
ECOG PS 0 24 68.6
1 10 28.6
2 1 2.9
Primary Site Sun-damaged skin 3 8.6
Non-sun-damaged skin 13 37.1
Acral 4 11.4
Ocular 7 20.0
Mucosal 1 2.9
Unknown 7 20.0
Abbreviations: HDAC¼ histone deacetylase; LDH¼ lactate dehydrogenase;
DTIC¼ dacarbazine; ECOG¼ Eastern Cooperative Oncology Group; PS¼ perfor-
mance status; ILP¼ isolated limb perfusion; GM-CSF¼ granulocyte–macrophage
colony-stimulating factor; IL-2¼ interleukin-2; IL-12¼ interleukin-12. Most patients
received more than one previous treatment. Some systemic agents were given in
combination.
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Figure 1 Mean plasma concentration– time curve of sagopilone after
single intravenous infusion of 16mgm2 sagopilone over 3 h (N¼ 9–10).
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determined in previous studies at the same dose and dosing
schedule.
Toxicity and adverse events
Chemotherapy was generally well tolerated and no grade 3 or
higher adverse events were attributable to treatment with
sagopilone. The most common adverse events included grade 1
and 2 haematological toxicity (40% of patients), and grade 1 and 2
motor (22.9%) and sensory neuropathy (51.4%). Of 12 patients
receiving more than two cycles of sagopilone, five (43%)
experienced grade 1 or 2 motor neuropathy and seven (58%)
experienced grade 1 or 2 sensory neuropathy. One patient who
received a total of 10 cycles of sagopilone required a one-time
treatment interruption for grade 2 motor neuropathy, and a
second patient who received a total of 20 cycles required a dose
reduction owing to grade 2 sensory neuropathy. Two patients died
before the first restaging scans. Both cases are reported in this
manuscript as treatment failures, although neither death was
thought related to treatment-associated toxicity: one patient opted
to enter hospice before follow-up imaging and the other had
sudden death not thought linked to treatment. Table 2 summarises
adverse events that were judged to be possibly, probably, or
definitely linked to sagopilone exposure.
Response
One patient had 20 cycles of sagopilone, had a complete response,
and has remained without evidence of disease progression (last
scan, February 2010), and two other patients had confirmed
partial responses. One patient had an unconfirmed partial
response with 48% tumour reduction by the RECIST criteria, but
after the next chemotherapy cycle, he had bleeding from a bladder
metastasis detected on cystoscopy that was thought to pre-date
treatment on study. The pre-existing nature of the lesion could
not be confirmed; however, since the patient did not undergo
pretreatment cystoscopy. Including this patient, the overall
objective response rate was 11.4%. In addition, eight patients
had stable disease for an interval of 12 weeks or longer, such that
12 of 35 patients (34.3%) derived clinical benefit from sagopilone
(Table 3). Eight of 12 patients deriving clinical benefit from
sagopilone had been treated with another chemotherapy regimen
previously. Only the 12 patients deriving clinical benefit from
sagopilone received more than two cycles of treatment and the
median number of sagopilone cycles received by patients
benefiting from treatment was 6. The median PFS was 7.5 weeks
(95% confidence interval (CI): 6.4–8.7 weeks) and the median OS
was 31.0 weeks (95% CI: 14.9–47.1 weeks; Figure 2).
Subgroup analysis
Patients showing a clinical benefit (combined complete response
þ partial responseþ stable disease) had a median OS not reached
at a median follow-up of 59.9 weeks, in comparison with patients
with progressive disease who had a median overall survival
of 24.4 weeks (Po0.01; Figure 3). Patients with LDH less than the
upper limit of normal had a longer survival than those with
an elevated LDH (median OS 55.9 weeks vs median OS of
20.6 weeks, Po0.001). No difference was seen for OS between
patients X60 compared with patients younger than 60, between
men and women, or between patients with stage IVA, IVB, and
IVC disease.
DISCUSSION
Treatment options in metastatic melanoma have been limited by
the lack of non-cross-resistant treatment options. As most effective
chemotherapy agents in melanoma are myelosuppressive, it is
Table 2 Percentage of 35 patients treated with sagopilone experiencing
adverse events by category
Grade (%)
Group Toxicity 1 2 Total (%)
Haematological Anaemia 8.6 8.6 17.2
Neutropenia 5.7 5.7 11.4
Thrombocytopenia 5.7 8.6 14.3
Cardiac Tachycardia 2.9 — 2.9
Pericardial effusion 2.9 — 2.9
Hypertension — 2.9 2.9
Constitutional Fatigue 25.7 5.7 31.4
Fever 5.7 — 5.7
Dermatological Alopecia 11.4 — 11.4
Rash 8.6 — 8.6
Dry skin 2.9 — 2.9
Gastrointestinal Anorexia 14.3 — 14.3
Nausea 31.4 — 31.4
Other 14.3 — 14.3
Laboratory Hepatic 5.7 2.9 8.6
Other 5.7 — 5.7
Neurological Motor neuropathy 8.6 14.3 22.9
Sensory neuropathy 45.7 5.7 51.4
Other 2.9 2.9 5.8
Pain 40.0 2.9 42.9
Respiratory Cough 5.7 — 5.7
Dyspnoea 2.9 — 2.9
Only the highest-grade event was included for each patient in each category.
No grade 3 or higher adverse events were observed.
Table 3 Best treatment response by the RECIST criteria
Best treatment response N %
Complete response 1 2.9
Partial response
Confirmed 2 5.7
Unconfirmed 1 2.9
Stable disease 8 22.9
Progressive disease 23 65.7
Total 35 100
Abbreviation: RECIST¼Response Evaluation Criteria in Solid Tumours.
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Figure 2 Progression-free survival (PFS) and overall survival (OS) in
33 evaluable patients.
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difficult to combine them without significant dose reduction.
Sagopilone notably lacks haematological toxicity. Data from this
study suggest that sagopilone may offer a new therapeutic
option that shows evidence of effectiveness and may be a good
candidate for combination regimens. Objective tumour responses
were seen in 11.4% of treated patients and 34.3% of patients had a
potential clinical benefit from sagopilone. The 12-month overall
survival in this study, 34.3%, also compares favourably to the
benchmark overall survival of 25.5% (95% CI: 23.6–27.4%)
established in a recent meta-analysis of over 2000 advanced
melanoma patients enrolled in phase II clinical trials (Korn et al,
2008).
Sagopilone appears to be more active than other tubulin-active
agents. Paclitaxel has been extensively studied in melanoma and
objective response rates in the first-line setting have ranged from
0 to 16% in small phase II trials (Einzig et al, 1991; Aamdal et al,
1994; Bedikian et al, 1995). The largest data set of paclitaxel-
treated melanoma patients using RECIST measurements is the
SYMMETRY Phase III trial in which paclitaxel monotherapy was
compared to paclitaxel with esclomolol. In this trial, objective
responses to paclitaxel were seen in only 4.4% of patients treated.
Paclitaxel is much less soluble than sagopilone and needs to be
formulated with Cremaphor EL, which can induce serious
hypersensitivity reactions in 11–18% of patients even with high-
dose steroid premedication (Einzig et al, 1991; Bedikian et al,
1995). Sagopilone, which does not require formulation with
Cremaphor EL, did not induce any signs or symptoms of hyper-
sensitivity reactions in this study even without steroid pretreat-
ment. Also in contrast to paclitaxel, grade 3 and 4 haemato-
logical toxicity was not observed, and no patient developed
febrile neutropenia. Although sagopilone penetrates the CNS,
neurological toxicity consisted primarily of mild-to-moderate
sensory neuropathy. Sagopilone also appears more active than
earlier generation epothilones that were also associated with higher
degrees of toxicity and little evidence of clinical benefit to
melanoma patients. Both patupilone and ixabepilone have been
tested in phase II trials and have shown no objective responses or
notable disease stabilisation (Pavlick et al, 2004; Daud, 2009).
Ixabepilone has significant haematological toxicity in addition to
neurotoxicity (Pavlick et al, 2004) and patupilone is associated
with GI toxicity, especially diarrhoea (Daud, 2009; Hussain et al,
2009).
The distinctive clinical profile of sagopilone may be, in part,
due to its unique pharmacokinetic and pharmacodynamic profile.
In in vitro assays, sagopilone localises almost exclusively to the
cytoskeletal compartment of melanoma cells, associates strongly
with microtubules, and induces tubulin polymerisation at a rate
that is approximately 50% higher than the rate observed in
melanoma cells treated with patupilone (Hoffmann et al, 2008).
More importantly, unlike some earlier generation epothilones,
sagopilone is rapidly and efficiently taken up into tumour cells,
and because it evades the MDR-1 efflux pump P-glycoprotein, it is
maintained within these cells (Klar et al, 2006; Hoffmann et al,
2008). Sagopilone biodistribution has previously been described as
multi-compartmental, with a high volume of distribution and high
clearance that likely indicate uptake into tissues and a slow release
(Schmid et al, 2010). In this study, with a larger cohort of patients,
we report AUC (252 vs 602 ng.hml1) and Cmax measurements
(33.3 vs 101 ng.hml1) lower than that observed previously.
Notably, the values previously reported by Schmid et al (2010)
were derived from a single patient and much more extensive prior
treatment was the norm in that study.
The majority of patients benefiting from sagopilone in this study
had been pretreated, suggesting that sagopilone may not be fully
cross-resistant with dacarbazine and/or platinum compounds. The
incidence of neurological toxicity was substantially lower than that
reported in a recent phase I trial (Schmid et al, 2010), perhaps
because patients in the previous study were more heavily
pretreated (median of previous regimens 3 vs 1) and more likely
to have had received previous neurotoxic agents, including
taxanes, vinca alkyloids, and platinum compounds. In addition,
sagopilone was not associated with significant haematological
toxicity in this study, making it a better choice for combination
therapy. These properties may be significant as the combination of
carboplatin and paclitaxel appears to be active in melanoma
(Hauschild et al, 2009a, b) and is emerging as a standard therapy
for metastatic melanoma. This regimen has several limitations;
these include its limited efficacy and cumulative haematological
toxicity. Sagopilone, with its activity and toxicity profile, is a viable
candidate for combination therapy.
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